We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
Healthcare and Pharmaceuticals industry

Global Proto-Oncogene Drug Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025




 

Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

With the slowdown in world economic growth, the Proto-Oncogene Drug industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Proto-Oncogene Drug market size to maintain the average annual growth rate of XXX from XXX million $ in 2014 to XXX million $ in 2019, Stratagem Market Insights analysts believe that in the next few years, Proto-Oncogene Drug market size will be further expanded, we expect that by 2026, The market size of the Proto-Oncogene Drug will reach XXX million $.

A proto-oncogene is a normal gene found in the cell and is involved in producing a protein involved in cell growth, division, and other processes in the cell. A mutation in proto-oncogene can turn the cell into a malfunctioning gene called an oncogene, which is a major cause of cancer.

Increasing prevalence of cancer is expected to boost growth of the global proto-oncogene drugs market over the forecast period. For instance, according to the World Health Organization, around 18.1 million new cases and 9.6 million deaths were registered due to cancer worldwide in 2018. Moreover, R&D in proto-oncogenes is also expected to aid in growth of the market. For instance, in February 2019, researchers from Al-Farabi Kazakh National University (Kazakhstan) and University of Pittsburgh Medical Center (U.S.) reported testing the c-myc proto-oncogene for its involvement in the mechanism of NK cell abnormalities in patients with lung and gastric cancer.

Increasing investment and funding in R&D of cancer and cancer treatment is expected to offer lucrative growth opportunities for players in the global proto-oncogene drugs market. For instance, according to the National Cancer Research Institute (NCRI), cancer research funding by NCRI partners reached around US$ 750 million in 2018/19. Similarly, in February 2020, AmorChem collaborated with Univalor, the Montreal Clinical Research Institute and McGill University for investment in R&D in c-Myc, a proto-oncogene implicated in over 50% of all human cancers.

However, high cost of and lack of awareness regarding proto-oncogene drugs is expected to hinder growth of the global proto-oncogene drugs market.

Major players in the market are focused on conducting clinical trials to expand their product portfolio. For instance, Pfizer, Inc., in collaboration with OxOnc Development LP, is conducting Phase II clinical trial for assessing the efficacy and safety of crizotinib in patients with advanced anaplastic lymphoma kinase-negative non-small cell lung cancer harboring a translocation or inversion involving the c-ROS oncogene (ROS1) locus. The study is expected to be complete in April 2020.

Major players in the market are also focused on product approval and launch to expand their product portfolio. For instance, in August 2019, Genentech, Inc., is a biotechnology corporation, received the U.S. Food and Drug Administration (FDA)’s accelerated approval for its Rozlytrek (entrectinib) — an inhibitor of tropomyosin receptor tyrosine kinases (TRK), proto-oncogene tyrosine-protein kinase ROS1 (ROS1), and anaplastic lymphoma kinase (ALK), for the treatment of non-small cell lung cancer.

Key Takeaways:

  • Increasing prevalence of cancer to augment growth of the global proto-oncogene drugs market over the forecast period
  • High cost of proto-oncogene drugs to hamper growth of the market
  • Major players operating in the global proto-oncogene drugs market include, ARIAD Pharmaceuticals, AstraZeneca, Bayer Healthcare, Bristol-Myers Squibb, ChemGenex Pharmaceuticals, Dexa Medica, Eisai Pharmaceuticals, Exelixis, GlaxoSmithKline, Novartis, Onyx Pharmaceuticals, Plexxikon, and Pfizer

This Report covers the manufacturers' data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.

Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

Section 1: Definition

Section (2 3): Manufacturer Detail

╼ ARIAD Pharmaceuticals
╼ AstraZeneca
╼ Bayer Healthcare
╼ Bristol-Myers Squibb
╼ ChemGenex Pharmaceuticals
╼ Dexa Medica
╼ Eisai Pharmaceuticals
╼ Exelixis
╼ GlaxoSmithKline
╼ Novartis
╼ Onyx Pharmaceuticals
╼ Plexxikon
╼ Pfizer

Section 4: Region Segmentation

╼ North America Country (United States, Canada)
╼ South America
╼ Asia Country (China, Japan, India, Korea)
╼ Europe Country (Germany, UK, France, Italy)
╼ Other Country (Middle East, Africa, GCC)

Section (5 6 7): Type Segmentation

Product Type Segmentation ➟
╼ Axitinib (Inlyta)
╼ Ponatinib (Iclusig)
╼ Imatinib (Gleevec)
╼ Sunitinib (Sutent)
╼ Pazopanib (Votrient)

Industry Segmentation ➟
╼ Clinic
╼ Hospital

Channel (Direct Sales, Distributor) Segmentation

Section 8: Trend (2019-2026)
Section 9: Product Type Detail
Section 10: Downstream Consumer
Section 11: Cost Structure
Section 12: Conclusion

Table of Contents

Section 1 Proto-Oncogene Drgu Product Definition

Section 2 Global Proto-Oncogene Drgu Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Proto-Oncogene Drgu Shipments
2.2 Global Manufacturer Proto-Oncogene Drgu Business Revenue
2.3 Global Proto-Oncogene Drgu Market Overview

Section 3 Manufacturer Proto-Oncogene Drgu Business Introduction
3.1 ARIAD Pharmaceuticals Proto-Oncogene Drgu Business Introduction
3.1.1 ARIAD Pharmaceuticals Proto-Oncogene Drgu Shipments, Price, Revenue and Gross profit 2014-2018
3.1.2 ARIAD Pharmaceuticals Proto-Oncogene Drgu Business Distribution by Region
3.1.3 ARIAD Pharmaceuticals Interview Record
3.1.4 ARIAD Pharmaceuticals Proto-Oncogene Drgu Business Profile
3.1.5 ARIAD Pharmaceuticals Proto-Oncogene Drgu Product Specification

3.2 AstraZeneca Proto-Oncogene Drgu Business Introduction
3.2.1 AstraZeneca Proto-Oncogene Drgu Shipments, Price, Revenue and Gross profit 2014-2018
3.2.2 AstraZeneca Proto-Oncogene Drgu Business Distribution by Region
3.2.3 Interview Record
3.2.4 AstraZeneca Proto-Oncogene Drgu Business Overview
3.2.5 AstraZeneca Proto-Oncogene Drgu Product Specification

3.3 Bayer Healthcare Proto-Oncogene Drgu Business Introduction
3.3.1 Bayer Healthcare Proto-Oncogene Drgu Shipments, Price, Revenue and Gross profit 2014-2018
3.3.2 Bayer Healthcare Proto-Oncogene Drgu Business Distribution by Region
3.3.3 Interview Record
3.3.4 Bayer Healthcare Proto-Oncogene Drgu Business Overview
3.3.5 Bayer Healthcare Proto-Oncogene Drgu Product Specification

3.4 Bristol-Myers Squibb Proto-Oncogene Drgu Business Introduction
3.5 ChemGenex Pharmaceuticals Proto-Oncogene Drgu Business Introduction
3.6 Dexa Medica Proto-Oncogene Drgu Business Introduction


Section 4 Global Proto-Oncogene Drgu Market Segmentation (Region Level)
4.1 North America Country
4.1.1 United States Proto-Oncogene Drgu Market Size and Price Analysis 2014-2018
4.1.2 Canada Proto-Oncogene Drgu Market Size and Price Analysis 2014-2018
4.2 South America Country
4.2.1 South America Proto-Oncogene Drgu Market Size and Price Analysis 2014-2018
4.3 Asia Country
4.3.1 China Proto-Oncogene Drgu Market Size and Price Analysis 2014-2018
4.3.2 Japan Proto-Oncogene Drgu Market Size and Price Analysis 2014-2018
4.3.3 India Proto-Oncogene Drgu Market Size and Price Analysis 2014-2018
4.3.4 Korea Proto-Oncogene Drgu Market Size and Price Analysis 2014-2018
4.4 Europe Country
4.4.1 Germany Proto-Oncogene Drgu Market Size and Price Analysis 2014-2018
4.4.2 UK Proto-Oncogene Drgu Market Size and Price Analysis 2014-2018
4.4.3 France Proto-Oncogene Drgu Market Size and Price Analysis 2014-2018
4.4.4 Italy Proto-Oncogene Drgu Market Size and Price Analysis 2014-2018
4.4.5 Europe Proto-Oncogene Drgu Market Size and Price Analysis 2014-2018
4.5 Other Country and Region
4.5.1 Middle East Proto-Oncogene Drgu Market Size and Price Analysis 2014-2018
4.5.2 Africa Proto-Oncogene Drgu Market Size and Price Analysis 2014-2018
4.5.3 GCC Proto-Oncogene Drgu Market Size and Price Analysis 2014-2018
4.6 Global Proto-Oncogene Drgu Market Segmentation (Region Level) Analysis 2014-2018
4.7 Global Proto-Oncogene Drgu Market Segmentation (Region Level) Analysis

Section 5 Global Proto-Oncogene Drgu Market Segmentation (Product Type Level)
5.1 Global Proto-Oncogene Drgu Market Segmentation (Product Type Level) Market Size 2014-2018
5.2 Different Proto-Oncogene Drgu Product Type Price 2014-2018
5.3 Global Proto-Oncogene Drgu Market Segmentation (Product Type Level) Analysis

Section 6 Global Proto-Oncogene Drgu Market Segmentation (Industry Level)
6.1 Global Proto-Oncogene Drgu Market Segmentation (Industry Level) Market Size 2014-2018
6.2 Different Industry Price 2014-2018
6.3 Global Proto-Oncogene Drgu Market Segmentation (Industry Level) Analysis

Section 7 Global Proto-Oncogene Drgu Market Segmentation (Channel Level)
7.1 Global Proto-Oncogene Drgu Market Segmentation (Channel Level) Sales Volume and Share 2014-2018
7.2 Global Proto-Oncogene Drgu Market Segmentation (Channel Level) Analysis

Section 8 Proto-Oncogene Drgu Market Forecast 2018-2023
8.1 Proto-Oncogene Drgu Segmentation Market Forecast (Region Level)
8.2 Proto-Oncogene Drgu Segmentation Market Forecast (Product Type Level)
8.3 Proto-Oncogene Drgu Segmentation Market Forecast (Industry Level)
8.4 Proto-Oncogene Drgu Segmentation Market Forecast (Channel Level)

Section 9 Proto-Oncogene Drgu Segmentation Product Type
9.1 Axitinib (Inlyta) Product Introduction
9.2 Ponatinib (Iclusig) Product Introduction
9.3 Imatinib (Gleevec) Product Introduction
9.4 Sunitinib (Sutent) Product Introduction
9.5 Pazopanib (Votrient) Product Introduction

Section 10 Proto-Oncogene Drgu Segmentation Industry
10.1 Clinic Clients
10.2 Hospital Clients

Section 11 Proto-Oncogene Drgu Cost of Production Analysis
11.1 Raw Material Cost Analysis
11.2 Technology Cost Analysis
11.3 Labor Cost Analysis
11.4 Cost Overview

Section 12 Conclusion

Chart and Figure
Figure Proto-Oncogene Drgu Product Picture from ARIAD Pharmaceuticals
Chart 2014-2018 Global Manufacturer Proto-Oncogene Drgu Shipments (Units)
Chart 2014-2018 Global Manufacturer Proto-Oncogene Drgu Shipments Share
Chart 2014-2018 Global Manufacturer Proto-Oncogene Drgu Business Revenue (Million USD)
Chart 2014-2018 Global Manufacturer Proto-Oncogene Drgu Business Revenue Share
Chart ARIAD Pharmaceuticals Proto-Oncogene Drgu Shipments, Price, Revenue and Gross profit 2014-2018
Chart ARIAD Pharmaceuticals Proto-Oncogene Drgu Business Distribution
Chart ARIAD Pharmaceuticals Interview Record (Partly)
Figure ARIAD Pharmaceuticals Proto-Oncogene Drgu Product Picture
Chart ARIAD Pharmaceuticals Proto-Oncogene Drgu Business Profile
Table ARIAD Pharmaceuticals Proto-Oncogene Drgu Product Specification
Chart AstraZeneca Proto-Oncogene Drgu Shipments, Price, Revenue and Gross profit 2014-2018
Chart AstraZeneca Proto-Oncogene Drgu Business Distribution
Chart AstraZeneca Interview Record (Partly)
Figure AstraZeneca Proto-Oncogene Drgu Product Picture
Chart AstraZeneca Proto-Oncogene Drgu Business Overview
Table AstraZeneca Proto-Oncogene Drgu Product Specification
Chart Bayer Healthcare Proto-Oncogene Drgu Shipments, Price, Revenue and Gross profit 2014-2018
Chart Bayer Healthcare Proto-Oncogene Drgu Business Distribution
Chart Bayer Healthcare Interview Record (Partly)
Figure Bayer Healthcare Proto-Oncogene Drgu Product Picture
Chart Bayer Healthcare Proto-Oncogene Drgu Business Overview
Table Bayer Healthcare Proto-Oncogene Drgu Product Specification
3.4 Bristol-Myers Squibb Proto-Oncogene Drgu Business Introduction

Chart United States Proto-Oncogene Drgu Sales Volume (Units) and Market Size (Million $) 2014-2018
Chart United States Proto-Oncogene Drgu Sales Price ($/Unit) 2014-2018
Chart Canada Proto-Oncogene Drgu Sales Volume (Units) and Market Size (Million $) 2014-2018
Chart Canada Proto-Oncogene Drgu Sales Price ($/Unit) 2014-2018
Chart South America Proto-Oncogene Drgu Sales Volume (Units) and Market Size (Million $) 2014-2018
Chart South America Proto-Oncogene Drgu Sales Price ($/Unit) 2014-2018
Chart China Proto-Oncogene Drgu Sales Volume (Units) and Market Size (Million $) 2014-2018
Chart China Proto-Oncogene Drgu Sales Price ($/Unit) 2014-2018
Chart Japan Proto-Oncogene Drgu Sales Volume (Units) and Market Size (Million $) 2014-2018
Chart Japan Proto-Oncogene Drgu Sales Price ($/Unit) 2014-2018
Chart India Proto-Oncogene Drgu Sales Volume (Units) and Market Size (Million $) 2014-2018
Chart India Proto-Oncogene Drgu Sales Price ($/Unit) 2014-2018
Chart Korea Proto-Oncogene Drgu Sales Volume (Units) and Market Size (Million $) 2014-2018
Chart Korea Proto-Oncogene Drgu Sales Price ($/Unit) 2014-2018
Chart Germany Proto-Oncogene Drgu Sales Volume (Units) and Market Size (Million $) 2014-2018
Chart Germany Proto-Oncogene Drgu Sales Price ($/Unit) 2014-2018
Chart UK Proto-Oncogene Drgu Sales Volume (Units) and Market Size (Million $) 2014-2018
Chart UK Proto-Oncogene Drgu Sales Price ($/Unit) 2014-2018
Chart France Proto-Oncogene Drgu Sales Volume (Units) and Market Size (Million $) 2014-2018
Chart France Proto-Oncogene Drgu Sales Price ($/Unit) 2014-2018
Chart Italy Proto-Oncogene Drgu Sales Volume (Units) and Market Size (Million $) 2014-2018
Chart Italy Proto-Oncogene Drgu Sales Price ($/Unit) 2014-2018
Chart Europe Proto-Oncogene Drgu Sales Volume (Units) and Market Size (Million $) 2014-2018
Chart Europe Proto-Oncogene Drgu Sales Price ($/Unit) 2014-2018
Chart Middle East Proto-Oncogene Drgu Sales Volume (Units) and Market Size (Million $) 2014-2018
Chart Middle East Proto-Oncogene Drgu Sales Price ($/Unit) 2014-2018
Chart Africa Proto-Oncogene Drgu Sales Volume (Units) and Market Size (Million $) 2014-2018
Chart Africa Proto-Oncogene Drgu Sales Price ($/Unit) 2014-2018
Chart GCC Proto-Oncogene Drgu Sales Volume (Units) and Market Size (Million $) 2014-2018
Chart GCC Proto-Oncogene Drgu Sales Price ($/Unit) 2014-2018
Chart Global Proto-Oncogene Drgu Market Segmentation (Region Level) Sales Volume 2014-2018
Chart Global Proto-Oncogene Drgu Market Segmentation (Region Level) Market size 2014-2018
Chart Proto-Oncogene Drgu Market Segmentation (Product Type Level) Volume (Units) 2014-2018
Chart Proto-Oncogene Drgu Market Segmentation (Product Type Level) Market Size (Million $) 2014-2018
Chart Different Proto-Oncogene Drgu Product Type Price ($/Unit) 2014-2018
Chart Proto-Oncogene Drgu Market Segmentation (Industry Level) Market Size (Volume) 2014-2018
Chart Proto-Oncogene Drgu Market Segmentation (Industry Level) Market Size (Share) 2014-2018
Chart Proto-Oncogene Drgu Market Segmentation (Industry Level) Market Size (Value) 2014-2018
Chart Global Proto-Oncogene Drgu Market Segmentation (Channel Level) Sales Volume (Units) 2014-2018
Chart Global Proto-Oncogene Drgu Market Segmentation (Channel Level) Share 2014-2018
Chart Proto-Oncogene Drgu Segmentation Market Forecast (Region Level) 2018-2023
Chart Proto-Oncogene Drgu Segmentation Market Forecast (Product Type Level) 2018-2023
Chart Proto-Oncogene Drgu Segmentation Market Forecast (Industry Level) 2018-2023
Chart Proto-Oncogene Drgu Segmentation Market Forecast (Channel Level) 2018-2023
Chart Axitinib (Inlyta) Product Figure
Chart Axitinib (Inlyta) Product Advantage and Disadvantage Comparison
Chart Ponatinib (Iclusig) Product Figure
Chart Ponatinib (Iclusig) Product Advantage and Disadvantage Comparison
Chart Imatinib (Gleevec) Product Figure
Chart Imatinib (Gleevec) Product Advantage and Disadvantage Comparison
Chart Sunitinib (Sutent) Product Figure
Chart Sunitinib (Sutent) Product Advantage and Disadvantage Comparison
Chart Pazopanib (Votrient) Product Figure
Chart Pazopanib (Votrient) Product Advantage and Disadvantage Comparison
Chart Clinic Clients
Chart Hospital Clients

 



Frequently Asked Questions

The report efficiently evaluates the market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Mn Units).
Market is segmented by Product Types, Drug Class, Indication, Applications, Services Types, End-users, Distribution channel, and Regions.
The report presents the current market size, and market forecast, market opportunities, key drivers and restraints, pipeline Analysis, incidence rate, epidemiology analysis, prevalence rate, regulatory scenario, industry trend, PESTLE analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing initiatives, pricing analysis, export-import analysis, trade analysis, competitive landscape which help businesses in decision making. The analysis data is based on current and historical market trends which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any organization to gain insight into specific business sector, aligned with specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.

Get In Touch

In search of customized market research solution? We are here to help you. Contact us.